

31 October 2022

2022/23 Invitation to Tender

The 2022/23 Invitation to Tender (2022/23 ITT) has been distributed today.

If you have already registered your e-mail address with Pharmac's tendering e-portal you can access the 2022/23 ITT in the e-portal in Current Tenders.

If you have not registered your company with the e-Portal, and you would like to participate in the 2022/23 ITT, please register at <https://in-tendhost.co.uk/pharmac.aspx/Home>.

A complete copy of the 2022/23 ITT is available on [our website](#). We will not be posting out any hard copies of the 2022/23 ITT.

If you wish to submit a Tender Bid in relation to community supply and/or hospital supply, you must submit it via the Electronic Portal to Pharmac no later than 4 pm (New Zealand time) on Thursday 15 December 2022.

Changes to the 2022/23 ITT product list

Please note that the product list (Schedule Two) consulted on in July 2022 has changed. Some products have been added, removed or amended either as a result of:

- clinical advice received (i.e. from the Tender Clinical Advisory Committee); and/or
- consultation responses received from suppliers, Te Whatu Ora, and/or medical groups; and/or
- a review of unresolved bids from previous tenders.

The following items have been added to the 2022/23 ITT:

Chemical Name	Line Item
Ace inhibitor	Oral liquid
Alendronate sodium	Tab 70 mg
Alendronate sodium with colecalciferol	Tab 70 mg with colecalciferol 5,600 iu
Atomoxetine	Cap 10 mg
Atomoxetine	Cap 18 mg
Atomoxetine	Cap 25 mg
Atomoxetine	Cap 40 mg
Atomoxetine	Cap 60 mg
Atomoxetine	Cap 80 mg
Atomoxetine	Cap 100 mg
Cefazolin sodium	Inj 2 g
Cetirizine hydrochloride	Tab 10 mg
Dabigatran	Cap 75 mg
Dabigatran	Cap 110 mg

Chemical Name	Line Item
Dabigatran	Cap 150 mg
Docetaxel	Inj 80 mg
Entecavir	Tab 0.5 mg
Etoposide	Cap 50 mg
Etoposide	Cap 100 mg
Etoposide phosphate	Inj 100 mg (of etoposide base)
Exemestane	Tab 25 mg
Ezetimibe (current access)	Tab 10 mg
Ezetimibe (widened access)	Tab 10 mg
Fentanyl	Inj 10 mcg per ml, 100 ml premixed bag
Flucloxacillin sodium	Inj 250 mg
Flucloxacillin sodium	Inj 500 mg
Fosfomycin (current access)	Powder
Fosfomycin (widened access)	Powder
Ketamine	Inj 100 mg per ml, 2 ml

Chemical Name	Line Item
Metoprolol succinate	Tab long-acting very low dose (20-25 mg)
Metoprolol succinate	Tab long-acting low dose (40-50 mg)
Metoprolol succinate	Tab long-acting medium Dose (90-100 mg)
Metoprolol succinate	Tab long-acting high dose (180-200 mg)
Moxifloxacin	Inj 400 mg
Nitrofurantoin	Cap modified-release 100 mg
Noradrenaline	Inj 0.06 mg per ml, 50 ml syringe
Noradrenaline	Inj 0.1 mg per ml, 50 ml syringe
Noradrenaline	Inj 0.1 mg per ml, 100 ml bag
Noradrenaline	Inj 0.12 mg per ml, 100 ml bag
Noradrenaline	Inj 0.16 mg per ml, 50 ml syringe
Permethrin (combined market)	Crm 5%
Permethrin (split market)	Crm 5%
Pyridostigmine bromide	Tab 60 mg
Rivaroxaban	Tab 10 mg

Chemical Name	Line Item
Rivaroxaban	Tab 15 mg
Rivaroxaban	Tab 20 mg
Sacubitril with valsartan (current access)	Tab 24.3 mg with valsartan 25.7 mg
Sacubitril with valsartan (current access)	Tab 48.6 mg with valsartan 51.4 mg
Sacubitril with valsartan (current access)	Tab 97.2 mg with valsartan 102.8 mg
Sacubitril with valsartan (widened access)	Tab 24.3 mg with valsartan 25.7 mg
Sacubitril with valsartan (widened access)	Tab 48.6 mg with valsartan 51.4 mg
Sacubitril with valsartan (widened access)	Tab 97.2 mg with valsartan 102.8 mg
Temozolomide	Cap 5 mg
Temozolomide	Cap 20 mg
Temozolomide	Cap 100 mg
Temozolomide	Cap 140 mg
Temozolomide	Cap 250 mg
Thiotepa	Inj 15 mg
Thiotepa	Inj 100 mg
Vecuronium	Inj 10 mg

The following items have been amended in the 2022/23 ITT:

Chemical Name	Line Item
Alfentanil	Inj 0.5 mg per ml, 2 ml ampoule
Allopurinol (febuxostat funded without restriction)	Tab 100 mg
Allopurinol (febuxostat funded without restriction)	Tab 300 mg
Allopurinol (febuxostat funding remains restricted)	Tab 100 mg
Allopurinol (febuxostat funding remains restricted)	Tab 300 mg
Ambrisentan	Tab 5 mg
Ambrisentan	Tab 10 mg
Amoxicillin	Grans for oral liq 125 mg per 5 ml
Amoxicillin	Grans for oral liq 250 mg per 5 ml

Chemical Name	Line Item
Amoxicillin clavulanate	Tab amoxyxcillin 500 mg with potassium clavulanate 125 mg
Aspirin	Tab 100 mg
Atracurium besylate	Inj 10 mg per ml, 2.5 ml
Atracurium besylate	Inj 10 mg per ml, 5 ml
Benzatropine mesylate	Inj 1 mg per ml, 2 ml ampoule
Benzylpenicillin sodium [Penicillin G]	Inj 600 mg
Cefitaxime	Inj 1 g
Ceftazidime	Inj 1 g
Cefuroxime sodium	Inj 750 mg
Cefuroxime sodium	Inj 1.5 g

Chemical Name	Line Item
Clarithromycin	Inj 500 mg
Clonidine	TDDS 2.5 mg, 100 mcg per day
Clonidine	TDDS 5 mg, 200 mcg per day
Clonidine	TDDS 7.5 mg, 300 mcg per day
Colecalciferol	Cap/tab 1.25 mg
Darunavir	Tab 400 mg
Darunavir	Tab 600 mg
Dexmedetomidine hydrochloride	Inj 100 mcg per ml, 2 ml vial
Febuxostat (current access)	Tab 80 mg
Febuxostat (current access)	Tab 120 mg
Febuxostat (widened access)	Tab 80 mg
Febuxostat (widened access)	Tab 120 mg
Flecainide acetate	Tab 50 mg
Flecainide acetate	Cap long-acting 100 mg
Flecainide acetate	Cap long-acting 200 mg
Hydrocortisone with wool fat and mineral oil	Lotn 1% with wool fat hydrour 3% and mineral oil
Hydroxyurea	Cap 500 mg
Hyoscine N-butylbromide	Inj 20 mg, 1 ml
Magnesium sulphate	Inj 2 mmol per ml, 5 ml
Melphalan	Inj 50 mg vial
Meropenem	Inj 1 g
Metaraminol tartrate	Inj 0.5 mg per ml, 5 ml
Metaraminol tartrate	Inj 0.5 mg per ml, 10 ml
Metaraminol tartrate	Inj 0.5 mg per ml, 20 ml
Metaraminol tartrate	Inj 1 mg per ml, 1 ml
Metaraminol tartrate	Inj 1 mg per ml, 10 ml
Metaraminol tartrate	Inj 10 mg per ml, 1 ml
Methotrexate	Inj 100 mg per ml, 50 ml
Metronidazole	Inj 5 mg per ml, 100 ml
Metyrapone	Cap 250 mg
Miconazole nitrate	Crn 2% (15 g – 20 g pack)

Chemical Name	Line Item
Morphine	Inj 1 mg per ml, 10 ml syringe
Morphine	Inj 1 mg per ml, 50 ml syringe
Morphine	Tab immediate-release 10 mg
Morphine	Tab immediate-release 20 mg
Oestriol	Tab 1 mg – 2 mg
Paracetamol	Inj 10 mg per ml, 100 ml
Permethrin (combined market)	Lotn 5%
Permethrin (split market)	Lotn 5%
Povidone iodine	Oint 10%
Remifentanil hydrochloride	Inj 1 mg
Remifentanil hydrochloride	Inj 2 mg
Rifampicin	Cap 150 mg
Rifampicin	Cap 300 mg
Rifampicin	Inj 600 mg
Rifampicin	Oral liq 100 mg per 5 ml
Ropivacaine hydrochloride	Inj 2 mg per ml, 10 ml ampoule
Ropivacaine hydrochloride	Inj 2 mg per ml, 20 ml
Ropivacaine hydrochloride	Inj 2 mg per ml, 100 ml
Ropivacaine hydrochloride	Inj 2 mg per ml, 200 ml
Ropivacaine hydrochloride	Inj 7.5 mg per ml, 10 ml
Ropivacaine hydrochloride	Inj 7.5 mg per ml, 20 ml
Ropivacaine hydrochloride	Inj 10 mg per ml, 10 ml
Ropivacaine hydrochloride	Inj 10 mg per ml, 20 ml
Roxithromycin	Tab 150 mg
Roxithromycin	Tab 300 mg
Suxamethonium chloride	Inj 50 mg per ml, 2 ml
Tacrolimus (current access)	Oint 0.1%
Tacrolimus (widened access)	Oint 0.1%
Tramadol hydrochloride	Cap 50 mg
Tramadol hydrochloride	Inj 50 mg per ml, 1 ml ampoule

Chemical Name	Line Item
Tramadol hydrochloride	Inj 50 mg per ml, 2 ml ampoule
Tramadol hydrochloride	Tab sustained-release 100 mg
Tramadol hydrochloride	Tab sustained-release 150 mg

Chemical Name	Line Item
Tramadol hydrochloride	Tab sustained-release 200 mg
Triamcinolone acetone	Inj 10 mg per ml, 1 ml
Urinary alkaliniser	Effervescent
Vancomycin hydrochloride	Inj 500 mg

The following items that were included in consultation have been removed from the 2022/23 ITT:

Chemical Name	Line Item
Azithromycin	Tab 250 mg
Bleomycin sulphate	Inj 15,000 iu vial

Chemical Name	Line Item
Cisplatin	Inj 1 mg per ml, 50 ml
Ganciclovir	Inj 500 mg vial

Additional Notes

Tramadol change in classification

On 3 May 2022 Cabinet released the [Misuse of Drugs \(Classification and Presumption of Supply\) Order 2022 and Misuse of Drugs \(Fentanyl and Tramadol\) Amendment Regulations 2022](#). The amendment reclassifies Tramadol as a controlled drug under the Misuse of Drugs Regulations 1977. Pharmac staff note that tramadol has been included in the final 2022/23 ITT and any tender bid for tramadol would have to comply with the legislation that relates to the new controlled drug classification of tramadol.

Appropriate pack-size and packaging type

Where possible, Pharmac has identified Tender Items where there is a specific product preference in Schedule Two of the 2022/23 ITT document. For example (highlighted in red):

Metronidazole						
Inj 5 mg per ml, 100 ml				H	5%	Preference for a bag presentation with space to add another antibiotic.
<u>Tab 200 mg</u>	368,077	\$48,807	\$0.1326	C H	5%	Preference for a scored, dispersible tablet
<u>Tab 400 mg</u>	2,140,052	\$532,980	\$0.2491	C H	5%	

While Pharmac has taken all reasonable care in identifying these preferences, it makes no representation as to the accuracy of this information and accepts no liability for any errors or omissions. Suppliers should always undertake their own due diligence before submitting any tender bids.

Please note: we have historically indicated a preference for the pack size of Tender Items supplied in the community to be either a 30-day or 90-day pack as this improves dispensing efficiency and reduces wastage. In the coming years we are intending to put greater emphasis on the appropriateness of both packaging type and pack size, with a preference for bottle packs for tablets and capsules where possible. In this Tender we have identified specific packaging preferences for individual products in Schedule 2, and we expect to expand this to a much wider range of products in future Tenders.

Oncology injectables

Te Whatu Ora hospitals are increasingly delivering chemotherapy treatment in satellite centers which require compounded products to have a shelf-life greater than 24 hours to account for delays in treatment transport and delivery. Due to this Pharmac has indicated a preference for products where stability data post-compounding is greater than 48 hours.

Ophthalmology Products (BAK-free)

For a number of Ophthalmology products, as indicated in Schedule Two of the 2022/23 ITT, Pharmac reserves its right to list a benzalkonium chloride (BAK) or preservative-free product for a restricted market. However, where a tender product is BAK-free it would have the entire market.

Access criteria

For a number of products as indicated in Schedule Two of the 2022/23 ITT document, Pharmac is tendering for current and/or widened access. Where clinical advice has been received regarding potential access criteria, links to this advice have been included below. Please note any access criteria stated via the links is indicative only and Pharmac reserves the right to amend these criteria.

Chemical Name	Line Item(s)
Capsaicin (Widened access)	Crm 0.075%
Ezetimibe (Widened access)	Tab 10 mg
Febuxostat (Widened access)	Tab 80 mg Tab 120 mg
Fosfmycin (Widened access)	Powder

Chemical Name	Line Item(s)
Sacubitril with valsartan (Widened access)	Tab 24.3 mg with valsartan 25.7 mg Tab 48.6 mg with valsartan 51.4 mg Tab 97.2 mg with valsartan 102.8 mg
Tacrolimus (widened access)	Oint 0.1%

Tacrolimus oint 0.1%

Pharmac are proposing to amend the prerequisites in the [Special Authority](#) and [Hospital Restriction](#) criteria for tacrolimus ointment as follows (amendments in bold and strikethrough).

- Patient has ~~atopic~~ dermatitis on the face; ~~and~~ **or**
- Patient has at least one of the following contraindications to topical corticosteroids: periorificial dermatitis, rosacea, documented epidermal atrophy or documented allergy to topical corticosteroids

Data estimates for PCT injectable products included in the 2022/23 ITT

Pharmac makes no representation as to the accuracy of this information or as to the level of sales or likely sales and, while Pharmac has taken all reasonable care in preparing the information set out below, it accepts no liability for any errors or omissions in the information.

In order to be fair to all suppliers, we are unlikely to provide any further data relating to tender items while the 2022/23 ITT remains open.

Usage data for PCT injectable products

Chemical	Total usage (mg) ¹
Docetaxel – Inj 1 mg for ECP	422,000
Docetaxel – inj 10 mg per ml, 8 ml vial	127,000
Etoposide phosphate – inj 1 mg (of etoposide base) for ECP	865,000
Etoposide phosphate -inj 100 mg (of etoposide base)	475,000
Gemcitabine hydrochloride – inj 1 g	2,570,000
Gemcitabine hydrochloride – inj 1 mg for ECP	7,253,000
Melphalan – inj 50 mg	80,000
Methotrexate – inj 1 mg for ECP	1,631,000
Methotrexate – inj 100 mg per ml, 50 ml vial	5,005,000
Paclitaxel – inj 1 mg for ECP	1,488,000
Paclitaxel – inj 30 mg	1,000
Paclitaxel – inj 100 mg	140,000
Paclitaxel – inj 300 mg	158,000

¹Usage rounded to the nearest 1000mg, for period between 1 July 2021 to 30 June 2022

These volumes are approximate and indicative only. Pharmac makes no representation as to the accuracy of these figures or as to the level of sales or likely sales of any tender item.

More information

If you have any queries regarding the tender or require any assistance with the e-portal please contact the Tender Analysts (James Anderson and Michael Chung) at tender@pharmac.govt.nz